Comparing IL-17 and Anti-TNF- Treatments on Platelet Counts and Disease Activity in Patients with Ankylosing Spondylitis Aged 16 to 60

What this Trial Is About

Researchers are studying ankylosing spondylitis AS, a chronic autoimmune disease causing inflammation in the spine and joints, often accompanied by symptoms like back pain, stiffness, and inflammation in hips, shoulders, and other areas. The study focuses on comparing the effects of two treatments, IL-17 inhibitors and anti-TNF alpha drugs, especially regarding their influence on platelet counts and how these relate to disease activity. The trial also considers the role of platelets in inflammation and the limitations of current disease activity measures. Participants in this observational study receive either IL-17 inhibitors or anti-TNF alpha treatments as part of their ongoing care. Researchers will compare platelet counts between these groups using complete blood count CBC tests. The study evaluates these effects over a 6-month period to understand how platelet levels associate with disease activity and inflammation control under these therapies. During the study, participants will have blood tests to measure platelet counts and assessments of their disease activity. Data collected will include patient-reported outcomes and laboratory markers like erythrocyte sedimentation rate and C-reactive protein. The study requires participants to be cooperative and able to provide informed consent. The total involvement spans at least six months, during which researchers monitor the relationship between platelet counts and disease status to better understand treatment impacts.

Effect of IL17 Inhibitor in Comparison With Anti-TNF in Patients With Ankylosing Spondylitis